Literature DB >> 7570983

Regulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes.

S S Ahuja1, S Shrivastav, D Danielpour, J E Balow, D T Boumpas.   

Abstract

Scarring, fibrosis, and immunosuppression occurs with chronic cyclosporine (CsA) administration. We postulated that CsA may induce transforming growth factor (TGF)-beta 1 secretion from human T lymphocytes, a cytokine with immunoregulatory effects that has been implicated in the pathogenesis of wound healing and scarring. TGF-beta 1 was measured in serum-free supernatants harvested from T lymphocytes stimulated in the presence of CsA by a specific sandwich ELISA. CsA (10-1000 ng/ml) enhanced TGF-beta 1 secretion by approximately 40-80% in a dose-dependent manner. Increased TGF-beta 1 secretion in the presence of CsA was accompanied by a 2- to 4-fold increase in TGF-beta 1 mRNA levels due to both enhancement of its nuclear transcription as well as prolongation of TGF-beta 1 mRNA half-life. To determine whether the increase in TGF-beta 1 secretion was also accompanied by a concomitant change in its receptor, TGF-beta 1 receptor expression was analyzed by cross-linking of radioiodinated TGF-beta 1. Unactivated T lymphocytes expressed both a 105-kDa and a 65-kDa TGF-beta receptor. Upon stimulation, a transient increase in receptor density was seen at 12 hr, followed by a decline at later time points. Cells treated with CsA exhibited at least 2-fold higher levels of TGF-beta receptors in a dose-dependent manner. Thus, CsA enhances the production of TGF-beta 1 protein as well as the expression of its receptor in activated T lymphocytes. Enhanced TGF-beta 1 production and binding may contribute to the immunosuppressive and fibrosis-promoting effects of CsA therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7570983     DOI: 10.1097/00007890-199510150-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Advances in the development of immunosuppressive agents in organ transplantation.

Authors:  T Ochiai; K Isono
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

2.  The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations.

Authors:  Hongbo Wang; Bartosz Grzywacz; David Sukovich; Valarie McCullar; Qing Cao; Alisa B Lee; Bruce R Blazar; David N Cornfield; Jeffrey S Miller; Michael R Verneris
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

Review 3.  The role of immunosuppression in lymphoma formation.

Authors:  I Penn
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs.

Authors:  J G Lunz; S Contrucci; K Ruppert; N Murase; J J Fung; T E Starzl; A J Demetris
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

5.  Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-beta 1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells.

Authors:  S Di Paolo; G Grandaliano; L Gesualdo; E Ranieri; F P Schena
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 6.  Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: interrogation by urinary cell mRNA profiling.

Authors:  Thangamani Muthukumar; John R Lee; Darshana M Dadhania; Ruchuang Ding; Vijay K Sharma; Joseph E Schwartz; Manikkam Suthanthiran
Journal:  Transplant Rev (Orlando)       Date:  2014-05-27       Impact factor: 3.943

7.  Cytokine gene expression during postnatal small intestinal development: regulation by glucocorticoids.

Authors:  C Schaeffer; M Diab-Assef; M Plateroti; F Laurent-Huck; J M Reimund; M Kedinger; C Foltzer-Jourdainne
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

Review 8.  A Comprehensive Review of Calcineurin Inhibitors Used for Immunosuppression in Cardiac Transplantation.

Authors:  Lydia R Engwenyu; Allen S Anderson
Journal:  Handb Exp Pharmacol       Date:  2022
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.